Articles related to BREAST CANCER

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.

The Trop-2-directed antibody-drug conjugate demonstrated a 2.3-month improvement in progression-free survival compared to standard chemotherapy options, offering a new treatment pathway for patients with limited options.

One in eight women will develop breast cancer in her lifetime, with risk-reducing medications showing up to 65% reduction in annual incidence, yet these interventions remain vastly underutilized in clinical practice.

The case highlights the critical importance of thorough documentation and appropriate follow-up care, regardless of a patient’s age or statistical likelihood of serious conditions.